Publications by authors named "Kengo Nakashima"

Purpose: To investigate whether long noncoding RNAs (lncRNAs) are involved in the development or malignant behavior of ovarian high-grade serous carcinoma (HGSC), we attempted to identify lncRNAs specific to HGSC.

Methods: Total RNAs were isolated from HGSC, normal ovarian, and fallopian tube tissue samples and were subjected to a PCR array that can analyze 84 cancer-associated lncRNAs. The lncRNAs that were upregulated and downregulated in HGSC in comparison to multiple samples of normal ovary and fallopian tube were validated by real-time RT-PCR.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to find long non-coding RNAs (lncRNAs) that are expressed unusually in ovarian high-grade serous carcinoma (HGSC) by analyzing RNA from various ovarian cell types.
  • - Using a PCR array, researchers pinpointed ten lncRNAs with altered expressions in HGSC cell lines—six were upregulated and four downregulated—and tested their effects on cell activities like proliferation, migration, and apoptosis.
  • - They discovered that overexpressing certain lncRNAs (MEG3 and POU5F1P5) inhibited cell migration, and the same four downregulated lncRNAs were also found to be low in actual HGSC tissue samples, indicating their potential significance in ovarian cancer.
View Article and Find Full Text PDF

Carbonyl reductase 1 (CBR1) has been reported to be involved in cancer progression. Recently, we found that CBR1 overexpression inhibited malignant behaviors and the epithelial mesenchymal transition (EMT) in uterine cervical cancer. It remained unclear whether this was also the case in uterine leiomyosarcoma (uLMS), which is derived from mesenchymal cells and is a much more malignant gynecological tumor.

View Article and Find Full Text PDF

Purpose: Carbonyl reductase 1 (CBR1) is involved in cancer progression. Recently, the authors reported that the loss of CBR1 expression is associated with a poor prognosis in uterine cervical cancer. Here, we investigated whether the decreased CBR1 expression promotes cancer progression by inducing the epithelial mesenchymal transition (EMT).

View Article and Find Full Text PDF